MedTrace Logo

Use of Stem Cells in Diabetes Mellitus Type 1

NCT02940418 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-07-24

No results posted yet for this study

Summary

Allogenic adipose derived mesenchymal stem cells will be injected into patients newly diagnosed with type 1 Diabetes Mellitus

Conditions

  • Diabetes Mellitus Type 1

Interventions

BIOLOGICAL

Adipose mesenchymal cells with bone marrow mononuclear cells

Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.

Sponsors & Collaborators

  • Sophia Al-Adwan

    lead OTHER

Principal Investigators

  • Abdallah Awidi, MD · Cell Therapy Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-19
Primary Completion
2019-11-30
Completion
2020-01-31

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02940418 on ClinicalTrials.gov